Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials - PubMed (original) (raw)
Meta-Analysis
Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials
Pınar Kızılırmak et al. Turk Kardiyol Dern Ars. 2017 Jan.
Free article
Abstract
Objective: Hypertension is the most prevalent modifiable risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality. This study aimed to assess the effects of renin-angiotensin-aldosterone system (RAAS) blockade on CV outcomes.
Methods: This study was designed according to the Preferred Reporting Items for Systemic reviews and Meta-Analyses statement. Databases were searched for articles published as of December 2014. Two sets of studies were selected. One set included randomized clinical trials comparing RAAS blocker (angiotensin II receptor blocker [ARB] or angiotensin-converting enzyme inhibitor [ACEI]) with placebo or active treatment. Second set included head-to-head randomized clinical trials comparing an ARB with an ACEI. Studies in both sets had reported any CV outcome parameter or death, i.e., all-cause mortality, CV mortality, emergence of CV events, myocardial infarction, cerebrovascular event, stroke, heart failure, and hospitalization for heart failure.
Results: Fifty-four pairwise comparisons of 51 trials with 277,609 patients were included. Statistically significant differences in favor of RAAS blockers vs non-RAAS blockers (risk ratio [RR] ranging from 0.805 to 0.967) were observed in terms of most CV outcomes, including all-cause mortality, CV mortality, CV events, myocardial infarction, heart failure and stroke. ARBs and ACEIs were found to be completely comparable (RR ranging from 0.923 to 1.090, all non-significant).
Conclusion: RAAS blockers are superior to medications other than RAAS blockers with respect to impact on CV outcomes in patients with hypertension. ARBs and ACEIs are comparable in terms of these outcomes.
Similar articles
- Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J. Cheng J, et al. JAMA Intern Med. 2014 May;174(5):773-85. doi: 10.1001/jamainternmed.2014.348. JAMA Intern Med. 2014. PMID: 24687000 - Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, Li J, Zhang J, Xu Y, Lu H, Xu D. Tai C, et al. BMC Cardiovasc Disord. 2017 Oct 5;17(1):257. doi: 10.1186/s12872-017-0686-z. BMC Cardiovasc Disord. 2017. PMID: 28982370 Free PMC article. - Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
Brugts JJ, van Vark L, Akkerhuis M, Bertrand M, Fox K, Mourad JJ, Boersma E. Brugts JJ, et al. Int J Cardiol. 2015 Feb 15;181:425-9. doi: 10.1016/j.ijcard.2014.11.179. Epub 2014 Nov 26. Int J Cardiol. 2015. PMID: 25569271 - The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH, Hall AS. Strauss MH, et al. Prog Cardiovasc Dis. 2016 Mar-Apr;58(5):473-82. doi: 10.1016/j.pcad.2015.11.004. Epub 2015 Nov 14. Prog Cardiovasc Dis. 2016. PMID: 26586276 Review.
Cited by
- NLRP3 inflammasome as a novel therapeutic target for heart failure.
Wang S, Zhang J, Wang Y, Jiang X, Guo M, Yang Z. Wang S, et al. Anatol J Cardiol. 2022 Jan;26(1):15-22. doi: 10.5152/AnatolJCardiol.2021.580. Anatol J Cardiol. 2022. PMID: 35191381 Free PMC article. - Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S, Volpe M. Omboni S, et al. Adv Ther. 2019 Feb;36(2):278-297. doi: 10.1007/s12325-018-0859-x. Epub 2018 Dec 27. Adv Ther. 2019. PMID: 30591990 Free PMC article. Review. - Pharmacotherapy for hypertension in adults 60 years or older.
Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Musini VM, et al. Cochrane Database Syst Rev. 2019 Jun 5;6(6):CD000028. doi: 10.1002/14651858.CD000028.pub3. Cochrane Database Syst Rev. 2019. PMID: 31167038 Free PMC article. - Pharmacotherapy for hypertension in adults aged 18 to 59 years.
Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Musini VM, et al. Cochrane Database Syst Rev. 2017 Aug 16;8(8):CD008276. doi: 10.1002/14651858.CD008276.pub2. Cochrane Database Syst Rev. 2017. PMID: 28813123 Free PMC article. Review. - Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis.
Zhang D, Wu H, Liu D, Li Y, Zhou G, Yang Q, Liu Y. Zhang D, et al. Front Cardiovasc Med. 2022 Dec 1;9:1036151. doi: 10.3389/fcvm.2022.1036151. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36531731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources